摘要
Background: The effect of selenoprotein P (SELENOP) levels on the sensitivity of cervical cancer patients to concurrent chemoradiotherapy (CCRT) has not been reported. In this study, the effects of the variations in plasma SELENOP levels on the sensitivity of cervical cancer patients to CCRT were investigated using metabonomics. @@@ Methods: Two patient groups were evaluated, i.e., the case group: 11 patients with intermediate to advanced primary squamous cervical cancer, who developed resistance against CCRT, and the sensitivity group: 11 patients who did not develop resistance were matched in a 1:1 ratio (controls). Blood samples were collected before and after CCRT, and the plasma SELENOP levels were measured by ELISA. The different metabolites present in the plasma were analyzed by UPLC-MS-MS. @@@ Results: SELENOP levels exhibited a significant reduction in both the resistant and sensitive groups after CCRT (F = 50.705, P < 0.001), and interaction effects between sensitivity and pre-and post-treatment on SELENOP levels were observed (F = 7.414, P = 0.013). Further, a more significant reduction in the SELENOP levels was observed in the CCRT-resistant group (mean reduction, 0.028 mu g/mL; P < 0.001) than in the sensitive group (mean reduction, 0.013 mu g/mL; P = 0.006). Four metabolic biomarkers, i.e., C18, C19, C20 sphingomyelin, and phosphatidylcholine 20:2/22:6, were shown to be differentially expressed between the resistant and sensitive groups pre-and post-treatment. C20 sphingomyelin levels exhibited a significant correlation with SELENOP levels (r = 0.326, P = 0.031). @@@ Conclusion: The levels of plasma SELENOP in the CCRT-resistant group decreased significantly, suggesting that SELENOP might affect the sensitivity by modulating lipid synthesis and metabolism.
学科与关键词
- Association of Plasma Selenium and Its Untargeted Metabolomic Profiling with Cervical Cancer PrognosisQi, Lei; Wang, Yuanyuan; Wang, Ruixiang; Wang, Mingxing; Jablonska, Ewa; Zhou, Huihui; Su, Shengqi; Jia, Yuehui; Zhang, Yiyi; Li, Qi*; Wang, Tong*Biological Trace Element Research, 2023, 201(10): 4637-4648.
- Using Circulating Tumor DNA (ctDNA) As Screening and Predictive Marker in Cervical Carcinoma Patients Receiving Radiation TherapyYang, J. L.; Fan, M.; Chen, M. H.; Pan, L.; Ma, J.; Lang, J.60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), San Antonio, TX, 2018-10-21 To 2018-10-24.
- Changes of immune microenvironment before and after chemoradiotherapy in cervical cancer.Sihan Liu; He, Qianru; Xing, Xiaodan; Sun, Tingting; Chuang QiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
